No benefit of 3,4-diaminopyridine in essential tremor: A placebo-controlled crossover study
- 13 June 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 66 (11) , 1753-1755
Abstract
3,4-Diaminopyridine (3,4-DAP) is a potassium channel blocker that has recently demonstrated an antioscillatory effect in humans by significantly reducing downbeat nystagmus. Based on the presumed role of intrinsic oscillations in the pathophysiology of essential tremor (ET), the authors conducted a double-blind, placebo-controlled crossover study assessing the antitremor effect of a single dose of 3,4-DAP in 19 patients with ET. They did not find any significant change in tremor severity as measured by clinical ratings or accelerometry.Keywords
This publication has 9 references indexed in Scilit:
- Tremor analysis in two normal cohortsClinical Neurophysiology, 2004
- Treatment of downbeat nystagmus with 3,4-diaminopyridineNeurology, 2003
- Arginine Vasotocin Interacts with the Social Environment to Regulate Advertisement Calling in the Gray Treefrog (Hyla versicolor)Brain, Behavior and Evolution, 2003
- Highly 4-aminopyridine sensitive delayed rectifier current modulates the excitability of guinea pig cerebellar Purkinje cellsExperimental Brain Research, 2001
- Thyroid Function and Obesity in Children and AdolescentsHormone Research in Paediatrics, 2000
- Animal models of tremorMovement Disorders, 1999
- The role of spectroscopy in parkinsonismMovement Disorders, 1998
- Assessing tremor severity.Journal of Neurology, Neurosurgery & Psychiatry, 1993
- Preliminary trial of 3,4‐diaminopyridine in patients with multiple sclerosisAnnals of Neurology, 1990